Shanghai Denovo officially launches Phase I clinical study of a new TLR8 agonist DN1508052-01

1545
Issuing time:2020-09-17 11:13

On September 10, Shanghai Denovo PharmaceuticalTechnology Co., Ltd., a subsidiary of Qingfeng Pharmaceutical Group, held aTLR8 agonist DN1508052-01 Phase I clinical trial kick-off meeting at ShanghaiDongfang Hospital, officially launching the project's Phase I clinical study.



XW202009173.png



XW202009172.png


Qingfeng Pharmaceutical Group Co.Ltd
Location:8 Zhandong Av., Zhanggong, Ganzhou, Jiangxi Province, China
Phone:+86-0797-5560800,5560600 Fax: +86-0797-5560620